Soterix Medical Inc., the global leader in non-invasive stimulation and integrated brain monitoring technologies, announced clearance from the U.S. Food & Drug Administration (FDA) for the SPRY Transcranial Magnetic Stimulation (TMS) Therapy. SPRY TMS is indicated for the treatment of Major Depressive Disorder in adult patients, who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.
"For clinicians prioritizing ergonomics and treatment flow, SPRY TMS provides unmatched convenience and performance," said Ms. Gina Polack, VP of Regulatory Affairs of Soterix Medical. "SPRY TMS is a compact multi-protocol all-in-one TMS therapy system."
Mr. Kamran Nazim, Chief Product Officer of Soterix Medical adds, "SPRY TMS complements Soterix Medical's unmatched range of non-invasive brain stimulation and measurement systems. And clinicians providing SPRY TMS leverage Soterix Medical's expansive US-based support and training."
Psychiatrists in the United States interested in incorporating the SPRY TMS system are eligible for Soterix Medical's Partnership program which includes support on the entire patient set-up pipeline, hands-on training and staff certification, financing options, and connection to our network of psychiatrists.
For more information please visit, www.soterixmedical.cpm
